EfficAcy and safety of carboPlatin, etoposide and atezOlizumab for the first-line treatment of patients with extensive-stage smaLL cell lung cancer in the real-wOrld setting.
Not Applicable
- Conditions
- Small cell lung cancer
- Registration Number
- JPRN-UMIN000038064
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 208
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are judged by the attending doctor as inappropriate to participate in this clinical research
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 6 months-PFS
- Secondary Outcome Measures
Name Time Method Overall survival Progression free survival Time to treatment failure Objective response rate Safety(severe toxicity) The difference of clinical outcomes between eligible and ineligible patients for Impower 133 trial